Switching off cancer genes

 
PROGEN Pharmaceuticals is making progress in a technology aiming to ‘switch off’ cancerous genes. 
A pre-clinical study found that Progen’s epigenetic technology is able to inhibit tumour-suppressing enzymes. CEO Justus Homburg is excited about the results.
“In epigenetics we try to switch genes to change how that cell behaves, how to stop it being cancerous rather than saying cancer cells are bad and let’s kill them off — it represents a big shift in the paradigm and that’s why epigenetics is so exciting,” explains Homburg.
But drug development is a lengthy process and Homburg predicts it could be another six years before the product PG11144 is fully developed and on the market as the first, second and third phases of trials still need to be carried out.
“Could it be a long term development? Yes, that could very well be the case, but it’s something well worth pursuing because it is a dramatic change,” he says.
Homburg points out the very risky nature of the drug development industry but he believes the technology’s potential is backed up by the data that shows it does have an effect on tumours.
“We think there’s an opportunity out there, but the vast majority of drug developments don’t succeed,” he says.
“We may be only able to target a specific cancer or a specific disease of a specific cancer – there’s a lot to learn but it’s potentially quite groundbreaking.”
Homburg is confident that Progen is in a good financial position and is comfortable with the company’s patent on the technology.
“One of the things to bear in mind is that we’ve been through a lot of corporate turmoil, but we have been able to put an awful lot of that behind ourselves and during that time pursued research in all of our products,” he says.
“These latest findings prove we have the technology, the expertise and the resources to progress our strong product pipeline.”

Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support

New report reveals 68 per cent of businesses are vulnerable to a cybersecurity attack

Partner Content
36 per cent of employees fear their organisation is at risk of financial losse...
SAI Global
Advertisement

Related Stories

Smartgroup shares plunge as suitor lowers takeover offer

Smartgroup shares plunge as suitor lowers takeover offer

Shares in Smartgroup (ASX: SIQ) have fallen back to where they were...

Go1 founders win Brisbane Young Entrepreneur of the Year Award after decade-long wait

Go1 founders win Brisbane Young Entrepreneur of the Year Award after decade-long wait

After their business became a unicorn amidst the ongoing expansion ...

Cardno shareholders to get a cut from $667m sale of international divisions

Cardno shareholders to get a cut from $667m sale of international divisions

Engineering and consulting group Cardno (ASX: CDD) has sold its US ...

Aurizon bulks up with $2.3 billion acquisition of One Rail Australia

Aurizon bulks up with $2.3 billion acquisition of One Rail Australia

Australia’s largest rail freight operator Aurizon (ASX: AZJ) ...